Looking for Another Target in Alzheimer Disease: Semorinemab

An anti-tau monoclonal antibody was not effective in prodromal-to-mild Alzheimer disease.

Presence of neurofibrillary tangles due to abnormal processing of tau is one of the pathological hallmarks of Alzheimer disease (AD). In this phase 2, industry-sponsored, international, randomized, double-blind, placebo-controlled, parallel-group trial, researchers tested the safety and efficacy of semorinemab, an investigational (not FDA-approved) monoclonal antibody targeting tau, in treating prodromal-to-mild AD. Participants met criteria for mild cognitive impairment (MCI) or dementia due to AD and had evidence of amyloid deposition based on cerebrospinal fluid (CSF) or amyloid positron emission tomography (PET) imaging. The 457 participants (mean age, 70 years, 56% female, >85% non-Hispanic white) were randomized in a 2:3:2:3 ratio to …

Reviewing Author

Jennifer Rose V. Molano, MD

Disclosures

Grant/Research SupportNational Center for Advancing Translational Science – Cincinnati Center for Clinical and Translational Science and Training

Editorial BoardsBrain & Life

Jennifer Rose V. Molano, MD

Disclosures

Grant/Research SupportNational Center for Advancing Translational Science – Cincinnati Center for Clinical and Translational Science and Training

Editorial BoardsBrain & Life

Looking for Another Target in Alzheimer Disease: Semorinemab

Topics

Reviewing Author